Výsledky vyhledávání - Dana E. Rathkopf
- Zobrazuji výsledky 1 - 20 z 65
- Přejít na další stránku
-
1
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer Autor Dana E. Rathkopf, Howard I. Scher
Vydáno 2013Revisão -
2
Apalutamide for the treatment of prostate cancer Autor Dana E. Rathkopf, Howard I. Scher
Vydáno 2018Revisão -
3
Treatment of Advanced Prostate Cancer Autor Min Yuen Teo, Dana E. Rathkopf, Philip W. Kantoff
Vydáno 2019Revisão -
4
-
5
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) Autor Deborah Bradley, Dana E. Rathkopf, Rodney L. Dunn, Walter M. Stadler, Glenn Liu, David C. Smith, Роберто Пили, James A. Zwiebel, Howard I. Scher, Maha Hussain
Vydáno 2009Artigo -
6
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer Autor Dana E. Rathkopf, Joel Picus, Arif Hussain, Susan Ellard, Kim Nguyen, Thomas Nydam, E. Allen-Freda, Kaushal Mishra, Maria Grazia Porro, Howard I. Scher, George Wilding
Vydáno 2013Artigo -
7
Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors Autor Monica Fornier, Dana E. Rathkopf, Manisha H. Shah, S. Patil, Eileen M. O’Reilly, Archie Tse, C. Hudis, Robert A. Lefkowitz, David P. Kelsen, Gary K. Schwartz
Vydáno 2007Artigo -
8
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer Autor Matthew R. Smith, Dana E. Rathkopf, Peter F.A. Mulders, Joan Carles, Hendrik Van Poppel, Jinhui Li, Thian Kheoh, Thomas W. Griffin, Arturo Molina, Charles J. Ryan
Vydáno 2015Artigo -
9
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer Autor Laura Graham, Kalyan Banda, Alba Torres, Brett S. Carver, Yu Chen, Katie Pisano, Greg Shelkey, Tracy Curley, Howard I. Scher, Tamara L. Lotan, Andrew C. Hsieh, Dana E. Rathkopf
Vydáno 2018Artigo -
10
Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide Autor Alexander Pan, Rachel Reingold, Jimmy L. Zhao, Andrea P. Moy, Lukas Kraehenbuehl, George Dranitsaris, Sean M. McBride, Howard I. Scher, Marisa Kollmeier, Han Xiao, Dana E. Rathkopf, Mario E. Lacouture
Vydáno 2022Artigo -
11
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer Autor Dana E. Rathkopf, Tomasz M. Beer, Yohann Loriot, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann S. de Bono, Bertrand Tombal, Teresa Parli, Suman Bhattacharya, De Phung, Andrew Krivoshik, Howard I. Scher, Michael J. Morris
Vydáno 2018Artigo -
12
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics Autor Bastien Nguyen, José Maurício Mota, Subhiksha Nandakumar, Konrad H. Stopsack, Emily S. Weg, Dana E. Rathkopf, Michael J. Morris, Howard I. Scher, Philip W. Kantoff, Anuradha Gopalan, Dmitriy Zamarin, David B. Solit, Nikolaus Schultz, Wassim Abida
Vydáno 2020Artigo -
13
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Can... Autor Matthew R. Smith, Emmanuel S. Antonarakis, Charles J. Ryan, William L. Berry, Neal D. Shore, Glenn Liu, Joshi J. Alumkal, Celestia S. Higano, Edna Chow Maneval, Rajesh Bandekar, Carla J. de Boer, Margaret K. Yu, Dana E. Rathkopf
Vydáno 2016Artigo -
14
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer Autor Jorge A. Carrasquillo, Joseph A. O’Donoghue, Neeta Pandit‐Taskar, John L. Humm, Dana E. Rathkopf, Susan F. Slovin, Matthew J. Williamson, Kristine Peregrino Lacuna, Anne-Kirsti Aksnes, Steven M. Larson, Howard I. Scher, Michael J. Morris
Vydáno 2013Artigo -
15
Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer Autor Emmanuel S. Antonarakis, Elisabeth I. Heath, David C. Smith, Dana E. Rathkopf, Amanda L. Blackford, Daniel C. Danila, Serina King, Anja S. Frost, A. Seun Ajiboye, Ming Zhao, Janet Mendonca, Sushant K. Kachhap, Michelle A. Rudek, Michael A. Carducci
Vydáno 2013Artigo -
16
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone Autor Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J. Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla J. de Boer, Margaret K. Yu, Howard I. Scher
Vydáno 2017Artigo -
17
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate can... Autor Diletta Bianchini, Aurelius Omlin, Carmel Pezaro, David Lorente, Roberta Ferraldeschi, Deborah Mukherji, Mateus Crespo, I. Figueiredo, Susana Miranda, Ruth Riisnaes, Andrea Zivi, Aby Buchbinder, Dana E. Rathkopf, Gerhardt Attard, Howard I. Scher, Johann S. de Bono, Daniel C. Danila
Vydáno 2013Artigo -
18
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL Autor Alan H. Bryce, Joshi J. Alumkal, Andrew J. Armstrong, Celestia S. Higano, Peter Iversen, Cora N. Sternberg, Dana E. Rathkopf, Yohann Loriot, Johann S. de Bono, Bertrand Tombal, Sarang Abhyankar, Po‐Han Lin, Andrew Krivoshik, D. Phung, Tomasz M. Beer
Vydáno 2017Artigo -
19
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer Autor Dana E. Rathkopf, Michael J. Morris, Josef J. Fox, Daniel C. Danila, Susan F. Slovin, Jeffrey H. Hager, Peter J. Rix, Edna Chow Maneval, Isan Chen, Mithat Gönen, Martin Fleisher, Steven M. Larson, Charles L. Sawyers, Howard I. Scher
Vydáno 2013Artigo -
20
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 Autor Johann S. de Bono, Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Eric J. Small, Neal D. Shore, Karim Fizazi, Peter De Porre, Thian Kheoh, Jinhui Li, Mary B. Todd, Charles J. Ryan, Thomas W. Flaig
Vydáno 2016Artigo
Vyhledávací nástroje:
Související témata
Medicine
Cancer
Internal medicine
Prostate cancer
Oncology
Androgen deprivation therapy
Urology
Androgen receptor
Abiraterone acetate
Prostate
Biology
Prednisone
Enzalutamide
Gene
Adverse effect
Cancer research
Chemotherapy
Clinical endpoint
Clinical trial
Confidence interval
Genetics
Hazard ratio
Disease
Hormone
Pathology
Pharmacology
Randomized controlled trial
Surgery
Castration
Docetaxel